Press Releases News and Media / Press Releases Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference May 24, 2019 Read More Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update March 6, 2019 Read More Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures February 26, 2019 Read More Xenon Pharmaceuticals Outlines 2019 Key Milestones January 6, 2019 Read More Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update November 6, 2018 Read More Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy September 6, 2018 Read More NINDS Launches New Epilepsy Center Without Walls August 1, 2018 Read More Pairnomix And KCNQ2 Cure Alliance Report Findings From Comprehensive Drug Screening In A Cellular Model Of KCNQ2 Epileptic Encephalopathy December 4, 2017 Read More Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial October 17, 2017 Read More Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy April 26, 2017 Read More 1 2 Next »
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference May 24, 2019 Read More
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update March 6, 2019 Read More
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures February 26, 2019 Read More
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update November 6, 2018 Read More
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy September 6, 2018 Read More
Pairnomix And KCNQ2 Cure Alliance Report Findings From Comprehensive Drug Screening In A Cellular Model Of KCNQ2 Epileptic Encephalopathy December 4, 2017 Read More
Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial October 17, 2017 Read More
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy April 26, 2017 Read More
